CD30/CD16A dual-specific teteal antibody combination K drug therapy R/R HL is better than single drug therapy

Affimed is a clinical immuno-oncology company dedicated to developing innovative therapies to fight cancer by restoring innant immunity in patients.
recently, the company announced that the results of a clinical study evaluating the treatment of recurring or refractic Hodgkin's lymphoma (R/R HL) phase Ib in the journal Hematology have been evaluated for the treatment of the AFM13 combination merca east anti-PD-1 therapy Keytruda (Corida, generic name: pembrolizumab, Pabliju monoantitor).
data show that AMF13 and Keytruda combined to achieve a higher objective remission rate (ORR) than Keytruda single-drug therapy, in particular: full remission rate (CR) doubled.
AFM13 is a pioneering (first-in-class) innate cell joint (ICE), a dual-specific teuteral antibody that targets CD30 and CD16 and specifically binds TOD30 on tumor cells and CD16A on natural immune cells such as NK cells and macrophages.
AFM13 uses the innate immune system's ability to fight tumors by binding and activating natural killer (NK) cells and macrophages to induce specific and selective killing of CD30-positive tumor cells.
AFM13 is a state-of-the-art ICE® clinical project from Affimed's ROCK platform and is currently being developed for the treatment of CD30-positive lymphoma.
published today is an indose-incremental study designed to assess the safety and initial efficacy of AFM13 in patients with R/R HL who had previously received multiple therapies.
the study included 30 R/R HL patients who had not received anti-PD-1 therapy (anti-PD-1 primary treatment) and had previously received at least two treatment failures, including brentuximab vedotin (BV).
results showed that: (1) independent review assessed that at the highest dose, the ORR for AFM13-Keytruda treatment was 88% and CR for 42% ;(2) the investigator reviewed and assessed that at the highest dose, the ORR for AFM13-Keytruda treatment was 88% and CR was 46%.
(3) subgroup analysis showed that the highest remission rate (ORR was 85% and CR was 46%) was observed in the subgroup of BV primary resopathic patients, and 11 of the 13 patients achieved objective remission.
these data have an advantage over the historical efficacy data of Keytruda single-drug therapy in similar patient groups: in the KEYNOTE-087 study, Keytruda single-drug treatment had ORR of 69% and CR of 22.4%.
the study, AFM13 and Keytruda were well-to-do and had similar safety requirements to those known for each drug.
most adverse events are low-level and can be controlled with standard care.
AFM13 suggests a new way to activate innate immunity through the CD16A targeted tumor cell killing capacity of NK cells and macrophages. The
1b study supports the idea that immuno-checkpoint inhibitors release the brakes of adaptive immune responses, and AMF13 complements PD-1 checkpoint inhibitors by combining drugs to trigger two branches of the immune system (innate and adaptive immune systems) simultaneously to fight tumors.
Andreas Harstick, chief medical officer of Affimed, said: "For the first time, we have demonstrated that the combination of ICE® and PD-1 checkpoint inhibitors is safe to use and that side effects are controllable.
of high and total remission rates seen in the AFM13 joint Keytruda concept validation study is very encouraging, suggesting that innate immunity activation can improve the efficacy of existing therapies.
"Source: Affimed Announcs Publications of Final Study Results of its Innate Cell Engager Candidate AFM13 in Combination with MSD's anti-PD-1 therapy KEYTRUDA? (pembrolizumab) in Blood Original title: Double the total mitigation rate! CD30/CD16A dual-specific teteal antibody combination K drug treatment Hodgkin's lymphoma is better than monotherapy